MTOR and colorectal carcinoma: These results suggest that xanthatin may inhibit the glycolytic pathway of CRC cells by targeting the mTOR signaling pathway, in compensation for the activation of oxidative phosphorylation metabolism in cells, thereby causing mitochondrial dysfunction and ultimately inhibiting the growth and metastasis of CRC cells.